Lipiviron AP Tablet contains a combination of Atorvastatin 20mg and Aspirin 150mg, formulated to provide dual therapeutic benefits in cardiovascular risk management. Atorvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers elevated low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels by inhibiting cholesterol biosynthesis in the liver, thereby reducing the risk of atherosclerosis and associated cardiovascular events. Aspirin, an antiplatelet agent, irreversibly inhibits cyclooxygenase-1 (COX-1), leading to decreased thromboxane A2 synthesis and subsequent inhibition of platelet aggregation, which helps prevent thrombus formation. The combination is indicated for patients at high risk of cardiovascular diseases, including those with a history of myocardial infarction, stroke, or established coronary artery disease, to reduce the incidence of major cardiovascular events. Lipiviron AP should be administered under medical supervision, with dosage tailored according to individual patient risk profiles and tolerance. Caution is advised in patients with active peptic ulcer disease, bleeding disorders, or hepatic impairment. Common adverse effects may include gastrointestinal discomfort, myalgia, and increased liver enzymes. Regular monitoring of lipid profiles, liver function tests, and bleeding parameters is recommended during therapy to ensure safety and efficacy.